October 9, 2019 Press release - Non-regulatory Targovax selected for oral presentation at Society for Immunotherapy of Cancer (SITC) 2019 Annual Meeting
September 24, 2019 Press release - Non-regulatory Targovax announces opening of Oslo University Hospital as site for ONCOS-102 trial in melanoma
August 12, 2019 Press release - Non-regulatory Targovax ASA: Announcement of second quarter and first half results 2019
July 31, 2019 Press release - Non-regulatory Targovax is invited to present at Solebury Trout European Biotech Investor Day in NYC
July 15, 2019 Press release - Non-regulatory Targovax announces start of the expansion part in the phase I/II trial with ONCOS-102 in combination with durvalumab in patients with advanced peritoneal malignancies
July 8, 2019 Press release - Regulatory Targovax announces encouraging results from part 1 of the ONCOS-102 and Keytruda combination trial in anti-PD1 refractory melanoma
June 18, 2019 Press release - Regulatory Targovax ASA: Registration of share capital increase following settlement of RSUs
June 13, 2019 Press release - Regulatory Targovax ASA: Mandatory notification of trade by primary insider following settlement of RSUs
June 12, 2019 Press release - Regulatory Targovax ASA: Settlement of restricted stock units and resolution to increase the share capital
June 6, 2019 Press release - Regulatory Targovax ASA: Mandatory notification of trade by primary insider in connection with settlement of RSUs
June 6, 2019 Press release - Regulatory Targovax ASA: Mandatory notification of trade by primary insider in connection with settlement of RSUs
June 5, 2019 Press release - Regulatory Targovax ASA: Completion of subsequent offering, registration of share capital increase
June 3, 2019 Press release - Non-regulatory Targovax announces publication of in vivo abscopal effect of ONCOS-102 and Keytruda combination
May 31, 2019 Press release - Regulatory Targovax ASA: Mandatory notification of trade by primary insider in connection with settlement of RSUs
May 24, 2019 Press release - Regulatory Targovax ASA: Last day of the subscription period in the subsequent offering
May 23, 2019 Press release - Regulatory TARGOVAX ASA – APPROVAL AND PUBLICATION OF SUPPLEMENTAL PROSPECTUS
May 23, 2019 Press release - Regulatory Targovax announces median and three-year overall survival for TG01 trial in resected pancreatic cancer
May 10, 2019 Press release - Regulatory Targovax ASA: Commencement of subscription period in the subsequent offering
May 8, 2019 Press release - Non-regulatory Targovax announces completed enrollment of ONCOS-102 trial in mesothelioma
May 2, 2019 Press release - Regulatory Targovax ASA: Issuance of restricted stock units (RSUs) to the board members
April 12, 2019 Press release - Regulatory TARGOVAX ASA – APPROVAL AND PUBLICATION OF SUPPLEMENTAL PROSPECTUS
March 28, 2019 Press release - Regulatory TARGOVAX ASA – REGISTRATION OF SHARE CAPITAL INCREASE FOLLOWING THE PRIVATE PLACEMENT
March 21, 2019 Press release - Regulatory TARGOVAX ASA – KEY INFORMATION RELATED TO THE SUBSEQUENT OFFERING
March 19, 2019 Press release - Non-regulatory Targovax is invited to present at Neoantigen Summit Europe, DNB SME Conference and BIO-Europe Spring
March 15, 2019 Press release - Regulatory Targovax signs clinical collaboration agreement with the Parker Institute for Cancer Immunotherapy and Cancer Research Institute
March 14, 2019 Press release - Non-regulatory Targovax grants Zelluna Immunotherapy an FTO license to intellectual property relating to mutant RAS T cell receptor technology
March 8, 2019 Press release - Non-regulatory Targovax announces Notice of Allowance in the US on patent covering the TG mutant-RAS neoantigen vaccine platform
February 11, 2019 Press release - Non-regulatory First patient treated in dose expansion cohort of Targovax’s ONCOS-102 trial in melanoma
February 4, 2019 Press release - Non-regulatory Targovax ASA: Announcement of fourth quarter and full year results 2018
January 21, 2019 Press release - Non-regulatory Targovax is invited to present at upcoming investor conferences
January 17, 2019 Press release - Non-regulatory Targovax granted European Patent for mutant-RAS neoantigen platform lead products
